

Supplementary Table 1. Comparison of demographics, differential baseline clinical characteristics and laboratory examinations for AMA-M2 positive individuals completing follow-up and individuals not available to follow-up

Characteristics	FU (n=1,808)		NA to FU (n=268)		P-value	Adjust P-value
	Available data (n)	Median (IQR) or n (%)	Available data (n)	Median (IQR) or n (%)		
Age	1,808	44 (33–53)	268	49 (41–57)	<0.001	<0.001
Female gender, n (%)	1,808	1088 (60.2%)	268	150 (56.0%)	0.190	0.190
BMI (kg/m ²)	1,798	23.50 (21.05–25.82)	266	24.29 (22.13–27.19)	<0.001	<0.001
Height (cm)	1,798	165.00 (159.00–171.00)	266	163.90 (157.75–171.00)	0.043	0.074
Waist (cm)	1,651	80.00 (72.00–88.00)	242	83.00 (75.00–91.00)	<0.001	<0.001
ALT (U/L)	1,808	16.00 (12.00–24.00)	268	21.00 (15.00–35.00)	<0.001	<0.001
TBIL (μmol/L)	1,808	10.20 (7.70–13.30)	268	10.60 (7.80–13.60)	0.179	0.210
DBIL (μmol/L)	1,808	3.80 (3.00–4.80)	268	3.90 (3.10–4.90)	0.128	0.171
ALP (U/L)	1,808	62.00 (51.00–74.00)	268	70.00 (57.00–87.00)	<0.001	<0.001
GGT (U/L)	1,808	18.00 (12.00–30.00)	268	33.00 (18.00–72.00)	<0.001	<0.001
AST (U/L)	1,808	18.00 (16.00–22.00)	268	21.00 (17.00–28.00)	<0.001	<0.001
IgM (g/L)	1,773	1.06 (0.75–1.47)	263	1.11 (0.78–1.68)	0.077	0.126
IgG (g/L)	1,774	11.72 (10.07–13.67)	263	11.39 (9.83–13.52)	0.152	0.195
IgA (g/L)	1,773	2.17 (1.65–2.77)	263	2.19 (1.73–2.91)	0.181	0.210
TP (g/L)	1,808	73.00 (70.00–76.00)	268	73.00 (70.00–76.00)	0.838	0.862
ALB (g/L)	1,808	46.00 (44.00–48.00)	268	46.00 (44.00–47.00)	0.109	0.160
A/G	1,808	1.70 (1.50–1.90)	268	1.70 (1.50–1.90)	0.168	0.209
Glu (mmol/L)	1,808	5.00 (4.70–5.40)	268	5.20 (4.80–5.60)	0.001	0.004
TG (mmol/L)	1,795	1.10 (0.78–1.61)	268	1.35 (0.87–1.97)	<0.001	<0.001
hs-CRP (mg/L)	1,754	0.59 (0.31–1.25)	267	0.77 (0.45–2.02)	<0.001	<0.001
RF (IU/mL)	1,803	5.50 (3.60–9.10)	267	5.90 (3.70–10.10)	0.122	0.168
CysC (mg/L)	1,553	0.77 (0.69–0.87)	232	0.81 (0.71–0.94)	<0.001	<0.001
Cr (umol/L)	1,788	67.00 (59.00–79.00)	268	67.00 (59.00–79.00)	0.956	0.956
TG-Ab (IU/L)	1,788	12.98 (10.00–19.44)	268	14.21 (11.00–24.57)	0.002	0.005
TPO-Ab (IU/L)	1,788	11.84 (9.00–16.26)	268	12.54 (9.00–18.69)	0.368	0.389
CA199 (U/mL)	1,808	6.00 (3.20–12.20)	268	6.70 (3.90–12.20)	0.312	0.340
CEA (ng/mL)	1,808	1.54 (1.03–2.31)	268	1.96 (1.37–2.75)	<0.001	<0.001
EOS% (%)	1,808	2.00 (1.30–3.30)	268	2.50 (1.50–4.10)	<0.001	<0.001
EOS# (×10 ⁹ /L)	1,808	0.12 (0.07–0.20)	268	0.15 (0.93–0.24)	<0.001	<0.001
HGB (g/L)	1,808	141.00 (133.00–154.00)	268	145.00 (134.00–156.00)	0.013	0.026
ESR (mm/h)	1,652	7.00 (3.00–12.00)	241	8.00 (4.00–13.00)	0.003	0.008
α1 (%)	1,805	3.30 (3.10–3.50)	268	3.40 (3.10–3.70)	0.014	0.026
β1 (%)	1,805	5.60 (5.30–6.00)	268	5.70 (5.40–6.10)	0.027	0.049
β2 (%)	1,805	4.70 (4.20–5.30)	268	4.80 (4.40–5.50)	0.007	0.015
γ (%)	1,805	17.00 (15.10–18.90)	268	16.80 (14.70–18.70)	0.245	0.276

Supplementary Table 1. Continued

Characteristics	FU (n=1,808)		NA to FU (n=268)		P-value	Adjust P-value
	Available data (n)	Median (IQR) or n (%)	Available data (n)	Median (IQR) or n (%)		
Alb%	1,805	61.30 (59.10–63.40)	268	60.90 (58.60–63.40)	0.084	0.132
A/G (Electrophoresis method)	1,792	1.60 (1.40–1.70)	268	1.60 (1.40–1.70)	0.111	0.160

A/G, Albumin/Globulin; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; CA199, Carbohydrate antigen199; CEA, carcinoembryonic antigen; Cr, creatinine; CysC, Cystatin C; DBIL, direct bilirubin; EOS, eosinophils; ESR, erythrocyte sedimentation rate; FU, AMA-M2 positive individuals completing follow-up; GGT, gamma-glutamyl transferase; Glu, blood glucose; HGB, hemoglobin; hs-CRP, hypersensitive-c-reactive-protein; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; IQR, interquartile range; NA to FU, AMA-M2 positive individuals not available to follow-up; RF, rheumatoid factor; TBIL, total bilirubin; TG, triglyceride; TG-Ab, anti-thyroglobulin antibodies; TP, total protein; TPO-Ab, anti-thyroid Peroxidase Antibody; α 1, α 1-microglobulin; β 1, β 1-globulin; γ , γ -globulin.